Investment Thesis
DiaMedica Therapeutics is a pre-commercial biotech company with unsustainable unit economics, burning 9.1M annually against only 500K in revenue. With 4.9M cash on hand providing less than 6.5 months of operational runway, the company faces imminent capital requirements or insolvency with no visible path to profitability.
Strengths
- Zero debt provides financial flexibility and eliminates refinancing risk
- Strong current ratio of 9.11x ensures adequate short-term liquidity coverage
- Stockholders equity of 47.2M provides asset backing relative to liabilities
Risks
- Critical cash depletion risk with 6.5-month runway at -9.1M annual operating cash burn rate
- Net losses deteriorating 34% year-over-year with minimal revenue generation and no demonstrated commercialization capability
- Zero insider activity over 90 days combined with unsustainable burn dynamics indicates existential viability concerns
Key Metrics to Watch
- Monthly operating cash burn rate and absolute cash position
- Revenue inflection and clinical trial progress toward commercialization
- Capital raise announcements and equity dilution impact on existing shareholders
Financial Metrics
Revenue
500.0K
Net Income
-10.0M
EPS (Diluted)
$0.00
Free Cash Flow
-9.1M
Total Assets
53.1M
Cash
4.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,096.4%
Net Margin
-2,008.4%
ROE
-21.3%
ROA
-18.9%
FCF Margin
-1,818.0%
Balance Sheet & Liquidity
Current Ratio
9.11x
Quick Ratio
9.11x
Debt/Equity
0.00x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T09:58:37.133030 |
Data as of: 2026-03-31 |
Powered by Claude AI